Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443727 | 0.89 | KMT2A (0.57) | HRH3KMT2A | |
| SCHEMBL3443417 | 0.89 | KMT2A (0.57) | HRH3KMT2A | |
| SCHEMBL3443170 | 0.89 | KMT2A (0.57) | HRH3KMT2A | |
| SCHEMBL2241250 | 0.89 | GBA1 (0.66) | GBA1KDM1AMAOB | |
| SCHEMBL27370800 | 0.88 | KMT2A (0.52) | HRH3KMT2A | |
| Hydrochloric Acid SCHEMBL6642879 | 0.88 | KMT2A (0.56) | HRH3KMT2A | |
| Hydrochloric Acid SCHEMBL1532936 | 0.87 | GBA1 (0.63) | GBA1MAOB | |
| SCHEMBL9093168 | 0.82 | HRH3 (0.49) | HRH3MAOB | |
| SCHEMBL13505378 | 0.82 | HRH3 (0.49) | HRH3MAOB | |
| SCHEMBL4892499 | 0.81 | GBA1 (0.78) | GBA1HRH3KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689720-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | Aventis Pharma S.A. (FR) | 2006-08-16 | — | — | EP | claimed |
| WO-2005051917-A9 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2005-09-29 | — | — | WO | claimed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | claimed |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2018-09-25 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| CN-104169258-B | novel heterocyclic carboxamides as modulators of kinase activity | 默克专利有限公司 | 2017-03-01 | — | — | CN | disclosed |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-2794571-B1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| EP-3049405-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | Pharmakea Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | HAVIV FORTUNA | 2006-02-09 | — | — | US | disclosed |
| WO-2006015150-A1 | CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF | CYLENE PHARMACEUTICALS (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | CYLENE PHARMACEUTICALS | 2006-02-02 | — | — | US | disclosed |
| WO-2005051917-A9 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA SA (FR) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005051917-A1 | PYRAZOLYL DERIVATIVES IN THE FORM OF DRUGS FOR TREATING ACUTE OR CHRONIC NEURONAL REGRESSIONS | AVENTIS PHARMA S.A. (FR) | 2005-06-09 | — | — | WO | disclosed |
| EP-1494672-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2004-01-22 | — | — | US | disclosed |
| WO-2003086398-A1 | AMINOCARBONYL SUBSTITUTED PYRIDINES, PYRIDAZINES, PYRIMIDINES, PYRAZINES AND TRIAZINES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | ABBOTT LABORATORIES | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014744-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | GBA1 2871/4885HRH3 2841/4885KDM1A 856/4885 |
| US-20030195195-A1 | Substituted pyridines having antiangiogenic activity | FLT1, FLT4, KDR | GBA1 2871/4885HRH3 2841/4885KDM1A 856/4885 |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | PIN1, HPD, DHPS | GBA1 2645/4885HRH3 1102/4885KDM1A 2437/4885 |
| US-10080753-B2 | Heterocyclic carboxamides as modulators of kinase activity | MAP3K15, MAP3K12, MAP3K11 | GBA1 2151/4885HRH3 1089/4885KDM1A 300/4885 |
| US-20160339028-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY | MAP3K19, MAP3K15, MAP3K12 | GBA1 1783/4885HRH3 966/4885KDM1A 263/4885 |
| US-20060030557-A1 | Substituted pyridines having antiangiogenic activity | FLT4, KDR, FLT1 | GBA1 2943/4885HRH3 2345/4885KDM1A 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.